Frontal fibrosing alopecia

Summary

Frontal fibrosing alopecia (MONDO:0016776) is a disease and 15 clinical trials. Top therapeutic interventions include cravacitinib, apremilast, and delgocitinib. A subtype of alopecia — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Prevalence: Unknown (Worldwide)
• Clinical trials: 15

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	frontal fibrosing alopecia
Mondo ID	MONDO:0016776
Orphanet	254492
ICD-11	1257078333
SNOMED CT	717055000
UMLS	C4255374
MedGen	899012
GARD	0010886
Is cancer (heuristic)	no

Also known as: FFA

Disease family

This is a subtype of alopecia. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › integumentary system disorder › disorder of pilosebaceous unit › hair anomaly › alopecia › frontal fibrosing alopecia

Related subtypes (25): alopecia, isolated, telogen effluvium, alopecia areata, chemotherapy-induced alopecia, alopecia mucinosa, atrichia with papular lesions, loose anagen syndrome, Satoyoshi syndrome, alopecia-intellectual disability-hypergonadotropic hypogonadism syndrome, hereditary hypotrichosis with recurrent skin vesicles, alopecia antibody deficiency, pseudopelade of Brocq, Quinquaud’s folliculitis decalvans, Graham Little-Piccardi-Lassueur syndrome, lichen planopilaris, hypotrichosis simplex, alopecia totalis, hypotrichosis simplex of the scalp, endocrine alopecia, alopecia universalis onychodystrophy vitiligo, central centrifugal cicatricial alopecia, ectodermal dysplasia alopecia preaxial polydactyly, Slti-Salem syndrome, microcephaly sparse hair intellectual disability seizures, alopecia universalis

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 15.

Phase distribution (across all retrieved trials)

Phase	Trials
Not specified	8
PHASE4	3
PHASE2	3
EARLY_PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT06240351	PHASE4	ACTIVE_NOT_RECRUITING	A Study to Evaluate the Safety and Efficacy of Baricitinib in the Treatment of Frontal Fibrosing Alopecia (FFA)
NCT03422640	PHASE4	UNKNOWN	Trial Evaluating the Efficacy of Apremilast for the Treatment of Frontal Fibrosing Alopecia
NCT03630198	PHASE4	COMPLETED	Pain Outcomes Following Intralesional Corticosteroid Injections
NCT07508488	PHASE2	RECRUITING	Deucravacitinib in the Treatment of Cicatricial Alopecias
NCT04409041	PHASE2	COMPLETED	Oral Low-Dose Naltrexone for Lichen Planopilaris and Frontal Fibrosing Alopecia
NCT05332366	PHASE2	COMPLETED	A Trial to Assess the Effect of Delgocitinib Cream 20 mg/g on the Molecular Signature, Safety, and Efficacy in Adults With Frontal Fibrosing Alopecia
NCT03346668	EARLY_PHASE1	COMPLETED	Role of Neurogenic Inflammation and Topical 6% Gabapentin Therapy in Symptomatic Scarring Alopecia
NCT07190534	Not specified	NOT_YET_RECRUITING	The Effectiveness of Hydroxychloroquine Versus Methotrexate in the Treatment of Frontal Fibrosing Alopecia in Routine Clinical Care: a Patient Preference Trial (FFA Trial)
NCT07340671	Not specified	NOT_YET_RECRUITING	Facial Papules in Frontal Fibrosing Alopecia (FFA)
NCT02467101	Not specified	UNKNOWN	Study to Assess the Efficacy of Intralesional Corticosteroid on the Treatment of Frontal Fibrosing Alopecia
NCT03082560	Not specified	UNKNOWN	Design and Validation of a New Assessment Tool for Lichen Planopilaris
NCT03335228	Not specified	WITHDRAWN	Platelet Rich Plasma for Frontal Fibrosing Alopecia
NCT04342091	Not specified	COMPLETED	Follicular Revival in Fibrosing Alopecia: Evaluating Use of Micro-needling
NCT06202560	Not specified	COMPLETED	Effectiveness and Safety of Tofacitinib in Patients With Recalcitrant Frontal Fibrosing Alopecia : A Pilot Study
NCT06512766	Not specified	COMPLETED	a Retrospective Study on the Systemic Treatment of LPP and FFA

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CRAVACITINIB	4	3
APREMILAST	4	1
DELGOCITINIB	3	1
CHEMBL475165	0	1
CHEMBL5421204	0	1